Who are Xencor, Inc.'s main suppliers?

Xencor, Inc. (XNCR) key suppliers include: KBI-BIOPHARMA-INC, OMERS, INCYTE. View the full supplier network at chainsifter.com/chain/XNCR.

Who are Xencor, Inc.'s major customers?

Xencor, Inc. (XNCR) key customers include: Gilead Sciences, Inc., Gilead Sciences, Inc., Johnson & Johnson, Johnson & Johnson, Novartis AG and 11 more. View the full customer network at chainsifter.com/chain/XNCR.

What sector is Xencor, Inc. in?

Xencor, Inc. (XNCR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

XNCR Supply Chain: Xencor, Inc. Supplier List & 22 Relationships

3Suppliers

16Customers

3Debt Items

20Related Chains

Xencor, Inc. Suppliers

Ticker	Name	Confidence	Evidence
KBI-BIOPHARMA-INC	KBI-BIOPHARMA-INC	92%	We have engaged KBI under the KBI Agreement for process development, clinical scale-up, analytical method development, formulation development, and other services related to drug substance and drug p…
OMERS	OMERS	90%	Pursuant to the Monjuvi Royalty Sale Agreement and subject to the Company’s existing license with Incyte, OMERS acquired the right to receive up to $ 29.3 million in royalties earned after July 1, 20…
INCYTE	INCYTE	80%	Pursuant to the Monjuvi Royalty Sale Agreement and subject to the Company’s existing license with Incyte, OMERS acquired the right to receive up to $ 29.3 million in royalties earned after July 1, 20…

Xencor, Inc. Customers

Ticker	Name	Confidence	Evidence
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from XNCR graph: these consolidated financial statem…
GILD	Gilead Sciences, Inc.	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from XNCR graph: these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Sign…
JNJ	Johnson & Johnson	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
NVSEF	Novartis AG	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from XNCR graph: these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Si…
TECH	Bio-Techne Corporation	72%	Reciprocal relationship from TECH graph: Reciprocal relationship from XNCR graph: old 8,093,712 shares of our common stock at the public offering price of $18.00 per share, which included the exercis…
TECH	Bio-Techne Corporation	72%	old 8,093,712 shares of our common stock at the public offering price of $18.00 per share, which included the exercise in full by the underwriters of their option to purchase 1,458,600 shares of our …
VIR	Vir Biotechnology, Inc.	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
VIR	Vir Biotechnology, Inc.	72%	Reciprocal relationship from VIR graph: Reciprocal relationship from XNCR graph: these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Sign…
VRDN	Viridian Therapeutics, Inc.	72%	Reciprocal relationship from VRDN graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from VRDN g…
VRDN	Viridian Therapeutics, Inc.	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
ZBIO	Zenas BioPharma, Inc.	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
ZBIO	Zenas BioPharma, Inc.	72%	Reciprocal relationship from ZBIO graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from ZBIO g…
AIMMUNE-THERAPEUTICS-INC	AIMMUNE-THERAPEUTICS-INC	62%	s to evaluate XmAb drug candidates. 2. Build and manage a pipeline of XmAb drug candidates. We advance multiple XmAb drug candidates into early stages of clinical development and evaluate data from s…
BIOMEDICAL-RESEARCH-INC	BIOMEDICAL-RESEARCH-INC	62%	, we earned $0.6 million in royalties from Vir. In June 2016, we entered into an agreement with Novartis Institutes for BioMedical Research, Inc. in which we provided Novartis with a non-exclusive li…

Xencor, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
XNCR-DEBT-13669	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2013-12-31.
XNCR-DEBT	Debt stack $175.2M	90%	Market cache reports total debt of $175.2M.
XNCR-DEBT-13668	Warrants outstanding: 0.01	90%	xbrl warrant detail from xbrl 2024-09-30.

Xencor, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Xencor, Inc..

Xencor, Inc. Ownership

Holder	Name	Confidence	Evidence
XNCR-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 206 tracked holders.

Xencor, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ALC	Alcon Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
SNNUF	Smith & Nephew plc	100.00	2
BHC	Bausch Health Companies Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	2
AVIR	Atea Pharmaceuticals, Inc.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
DNTH	Dianthus Therapeutics, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
CLGN	CollPlant Biotechnologies Ltd.	100.00	2

Xencor, Inc. Supply Chain